Spyre Therapeutics Added to the Nasdaq Biotechnology Index
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced Spyre has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 23, 2024.
馬薩諸塞州沃爾瑟姆，2024年12月18日 /PRNewswire/ -- Spyre Therapeutics, Inc. (納斯達克: SYRE) 是一家臨床階段的生物技術公司，利用最先進的抗體工程、合理的治療組合和精準醫學方法，旨在提高對炎症性腸病（"IBD"）的治療效果和便利性。今天宣佈，Spyre已被納入納斯達克生物技術指數（納斯達克: NBI），生效時間爲2024年12月23日（星期一）市場開放前。
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
NBI旨在跟蹤在納斯達克證券市場上市的一組證券的表現，這些證券根據行業分類基準被歸類爲生物技術或藥品。納斯達克生物技術指數中的公司必須滿足資格要求，包括最低市值、平均每日成交量和作爲公衆公司的上市年限等其他標準。NBI每年在12月進行評估，並採用修改後的市值加權方法進行計算。
For more information about the Nasdaq Biotechnology Index, please visit this link.
有關納斯達克生物技術指數的更多信息，請訪問此鏈接。
About Spyre Therapeutics
關於Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at .
Spyre Therapeutics是一家臨床階段的生物技術公司，旨在通過結合最先進的抗體工程、合理的治療組合和精準醫學方法，創造下一代炎症性腸病（IBD）產品。Spyre的產品線包括針對α4β7、TL1A和IL-23的延長半衰期抗體。有關更多信息，請訪問Spyre的官方網站。
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
在社交媒體上關注Spyre Therapeutics: @spyretx 和LinkedIn
SOURCE Spyre Therapeutics, Inc.
信息來源：Spyre Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。
